Could Big Pharma cash in on COVID vaccine?
Pfizer and Moderna could be looking at a big check once their first round of COVID vaccines are distributed, despite a non-lucrative market and pressure to keep costs low. But the key for both companies may lie in the patenting process. Quartz reporter Annalisa Merelli joined CBSN AM to explain how the COVID vaccine compares to other vaccines on the market and why the mRNA patent could have larger implications outside of coronavirus. She also gave insight to life inside Bergamo, Italy, one of the hardest-hit town earlier on in the pandemic.